What treatment options exist for patients with cGVHD with cutaneous sclerosis?
Prednisone and cyclosporine have been described in the initial management of cGVHD. Additional therapies with anecdotal evidence include phototherapy, extracorporeal photopheresis, sirolimus, imatinib, thalidomide, and rituximab. Prevention strategies aimed at reducing the risk of cGVHD include the use of antithymocyte globulin in the pretransplant period as well as cyclosporine, IVIG, and rituximab in the posttransplant period.
